Jerusalem, Israel and Lund, Sweden, September 11, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented data further illuminating the novel, dual mechanism of action (MOA) of investigational oral, once-daily, laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS), conferring neuroprotective and anti-inflammatory properties. Results from several preclinical studies suggest that laquinimod elicits a protective therapeutic effect by reducing demyelination and inducing axonal protection.
Read the complete press release below.
|
Contact: |
Elana Holzman Kevin Mannix |
Teva Pharmaceutical Industries Ltd. Teva North America |
+972-(3)-926-7554 +1-(215)-591-8912 |
|
|
Tomas Leanderson Göran Forsberg |
Active Biotech AB
Active Biotech AB |
+46-46-19-20-95
+46-46-19-11-54
|
